GSK plc

LSE GSK.L

GSK plc Total Non-Current Liabilities for the year ending December 31, 2023: USD 31.99 B

GSK plc Total Non-Current Liabilities is USD 31.99 B for the year ending December 31, 2023, a -2.83% change year over year. Total non-current liabilities are the sum of long-term debt and other non-current liabilities.
  • GSK plc Total Non-Current Liabilities for the year ending December 31, 2022 was USD 32.92 B, a -28.64% change year over year.
  • GSK plc Total Non-Current Liabilities for the year ending December 31, 2021 was USD 46.13 B, a -9.85% change year over year.
  • GSK plc Total Non-Current Liabilities for the year ending December 31, 2020 was USD 51.18 B, a 3.59% change year over year.
  • GSK plc Total Non-Current Liabilities for the year ending December 31, 2019 was USD 49.40 B, a 21.56% change year over year.
Key data
Date Total Non-Current Liabilities Shareholders' Equity Other Liabilities Total Liabilities
Market news
Loading...
SV Wall Street
LSE: GSK.L

GSK plc

CEO Ms. Emma Natasha Walmsley
IPO Date July 1, 1988
Location United Kingdom
Headquarters 980 Great West Road
Employees 70,212
Sector Healthcare
Industries
Description

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Similar companies

NG.L

National Grid plc

USD 12.27

1.04%

VOD.L

Vodafone Group Public Limited Company

USD 0.87

2.34%

BP.L

BP p.l.c.

USD 5.22

-0.21%

ULVR.L

Unilever PLC

USD 57.67

0.49%

AZN.L

AstraZeneca PLC

USD 140.24

-0.22%

StockViz Staff

February 4, 2025

Any question? Send us an email